Friedlander M, Kaye S B, Sullivan A, Atkinson K, Elliott P, Coppleson M, Houghton R, Solomon J, Green D, Russell P
Gynecol Oncol. 1983 Oct;16(2):275-81. doi: 10.1016/0090-8258(83)90102-6.
Thirty-five patients with advanced cervical cancer were treated with a combination chemotherapy regimen comprising cisplatin, vinblastine, and bleomycin (PVB). Sixty-six percent of 33 evaluable patients showed objective tumor response and complete remissions were seen in six (18%) patients. The median duration of tumor response in patients with recurrent cervical cancer was 24 weeks (range 8 to 104 weeks). Multivariate analysis of pretreatment variables including prior radiotherapy did not identify patients with a higher response probability. Nausea and vomiting were usual side effects of chemotherapy and there was one definite treatment-related death. Cervical cancer is responsive to cisplatin based combination chemotherapy. The role of chemotherapy in conjunction with radiotherapy or surgery in the treatment of locally advanced cervical cancer remains to be defined.
35例晚期宫颈癌患者接受了由顺铂、长春碱和博来霉素（PVB）组成的联合化疗方案治疗。33例可评估患者中，66%出现了客观肿瘤反应，6例（18%）患者达到完全缓解。复发性宫颈癌患者肿瘤反应的中位持续时间为24周（范围8至104周）。对包括既往放疗在内的预处理变量进行多因素分析，未发现反应概率较高的患者。恶心和呕吐是化疗常见的副作用，有1例明确与治疗相关的死亡。宫颈癌对基于顺铂的联合化疗有反应。化疗联合放疗或手术在局部晚期宫颈癌治疗中的作用仍有待确定。
